glomerular disease
Conditions
Interventions
cotimoxazole group:Receive mycophenolate mofetil(MMF) at 1-2 g/d for =12 weeks. Oral cotrimoxazole was initiated on the same day as the MMF treatment and was administered orally as 1 tablet once daily
Non-cotrimoxazole group:Receivemycophenolate mofetil(MMF) at 1-2 g/d for =12 weeks. No prophylactic application of cotrimoxazole.
Sponsors
The First Affiliated Hospital of the Air Force Military Medical University of the People's Liberation Army of China
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Written informed consent was obtained; (2) Aged 18-80 years; (3) Patients with a confirmed diagnosis of glomerulonephritis (both primary and secondary glomerulonephritis) who are also receiving MMF treatment at the same time.
Exclusion criteria
Exclusion criteria: (1) Hypersensitivity to sulfamethoxazole and methotrexate components; (2) Evidence of active infection within 3 weeks before enrolment; (3) Use of antimicrobial drugs within 10 days before enrolment; (4) Combination of other diseases: positive serological index of HBV; congenital or acquired immunodeficiency; active infection or clinical evidence of active tuberculosis or active cytomegalovirus infection; history of peptic ulcer and/or gastrointestinal bleeding; agranulocytosis; malignant neoplasm; serious cardiovascular diseases such as congenital heart disease, arrhythmia, heart failure; serious mental illness; (5) Women of childbearing age who are pregnant, have failed to use contraception, are breastfeeding, or are unable or unwilling to use adequate contraception. (6) Administer steroids and cyclophosphamide for the first three months of enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Routine blood test;urine routine;urinate frequently;kidney function;haemonium;blood lipid;immunoglobulin;complement;blood sedimentation;C-reactive protein;Calcitoninogen; interleukin-6;blood endotoxin quantification (LPS);galactomannan test; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood 1,3-ß-D glucan; | — |
Countries
china
Contacts
Public Contactlijie He
Xijing Hospital
Outcome results
None listed